Apolipoprotein E (APOE) (N-Term) Peptide
Quick Overview for Apolipoprotein E (APOE) (N-Term) Peptide (ABIN973324)
Target
Origin
Source
Application
-
-
Protein Region
- N-Term
-
Sequence
- LMDETMKELK AYKSELEEQL TPVAEETRAR LSKELQAAQA RLGADMEDVC
-
Characteristics
- This is a synthetic peptide designed for use in combination with anti-APOE Antibody. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
-
Purification
- Purified
-
-
-
-
Application Notes
- Each Investigator should determine their own optimal working dilution for specific applications.
-
Restrictions
- For Research Use only
-
-
-
Format
- Lyophilized
-
Reconstitution
- Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
-
Concentration
- 1 mg/mL
-
Buffer
- Final peptide concentration is 1 mg/mL in PBS.
-
Handling Advice
- Avoid repeated freeze-thaw cycles.
-
Storage
- -20 °C
-
Storage Comment
- For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
-
-
- APOE (Apolipoprotein E (APOE))
-
Background
-
Chylomicron remnants and very low density lipoprotein (VLDL) remnants are rapidly removed from the circulation by receptor-mediated endocytosis in the liver. Apolipoprotein E, a main apoprotein of the chylomicron, binds to a specific receptor on liver cells and peripheral cells. ApoE is essential for the normal catabolism of triglyceride-rich lipoprotein constituents. The APOE gene is mapped to chromosome 19 in a cluster with APOC1 and APOC2. Defects in apolipoprotein E result in familial dysbetalipoproteinemia, or type III hyperlipoproteinemia (HLP III), in which increased plasma cholesterol and triglycerides are the consequence of impaired clearance of chylomicron and VLDL remnants.
Alias Symbols: AD2, LDLCQ5, LPG, MGC1571
Protein Size: 317 -
Molecular Weight
- 34 kDa
-
Gene ID
- 348
-
NCBI Accession
- NM_000041, NP_000032
-
UniProt
- P02649
Target
-